I Must Find a Way to Keep Heart Failure Progression From Coming

Newark, DE US
January 16, 2020

The purpose of this presentation is to highlight the recommendations made by the ACC/AHA/HFSA 2017 heart failure guidelines regarding appropriate use of sacubitril/valsartan, Ivabradine, and intravenous iron therapy. In additional, the clinical evidence that created the foundation from which these recommendations were derived will be reviewed for a more thorough understanding of the benefits associated with implementation in appropriate patients with heart failure. By reviewing the guidelines and the literature, pharmacists in attendance will be further equipped to recognize patients that may benefit from the addition of these agents to their care, recommend initiation, cessation, or avoidance of these therapies based on patient specific criteria, and participate in interdisciplinary, collaborative discussions aimed at optimizing patient care for patients with heart failure. Pharmacy technicians will be equipped with the knowledge of these medications and increased familiarity that will enhance recognition when these medications are ordered or dispensed.

Target Audience

  • Pharmacists
  • Pharmacy technicians

Learning Objectives

Pharmacist learning objectives

  1. Identify patients that may benefit from the addition of sacubitril/valsartan to their heart failure regiment
  2. Define the criteria that must be met in order to initiate Ivabradine in patients with heart failure
  3. Explain the benefit of intravenous iron therapy for patients with HF and iron deficiency anemia

Pharmacy technician learning objectives

  1. Recognize the different medications used to manage HF

Additional Information

Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance
Course opens: 
01/16/2020
Course expires: 
02/29/2020
Event starts: 
01/16/2020 - 12:00pm
Event ends: 
01/16/2020 - 1:00pm
Cost:
$0.00
ChristianaCare
4755 Ogletown-Stanton Rd.
Newark, DE 19713
United States

Relevant financial relationships: Planning committee members and the presenter have nothing to disclose

Planning committee members

Erica M. McGovern, PharmD, MS
PGY-1 Pharmacy Resident
ChristianaCare
 
Laura Zizza, PharmD
Clinical Pharmacy Specialist
ChristianaCare
 
Course reviewer
James Lichauer, PharmD, BCPS, FASHP
PI Program Director, Pharmacy
Vizient
 
Presenter
Erica M. McGovern, PharmD, MS
PGY-1 Pharmacy Resident
ChristianaCare
Joint Accreditation Statement:
 
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and ChristianaCare.  Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
____________________________________________
 
Designation Statements:
 
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
Universal Activity Number: JA0006103-9999-20-023-L01-P
Universal Activity Number: JA0006103-9999-20-023-L01-T
CEU
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CEU – Attendance

Price

Cost:
$0.00
Please login or register to take this course.